Ladenburg Thalmann Financial Services’s Insight Molecular Diagnostics IMDX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Sell	25 -100	-80%	-$3.61K	﹤0.01%	5214
2019 Q3	$5K	Sell	125 -250	-67%	-$9.82K	﹤0.01%	4693
2019 Q2	$19K	Buy	375 +350	+1,400%	+$29.1K	﹤0.01%	4085
2019 Q1	$2K	Hold	25	–	–	﹤0.01%	4955
2018 Q4	$1K	Hold	25	–	–	﹤0.01%	5067
2018 Q3	$1K	Hold	25	–	–	﹤0.01%	5013
2018 Q2	$1K	Hold	25	–	–	﹤0.01%	5005
2018 Q1	$1K	Hold	25	–	–	﹤0.01%	5005
2017 Q4	$2K	Buy	+25	New	+$2.82K	﹤0.01%	4794
2016 Q4	–	Sell	-1	Closed	–	–	4920
2016 Q3	$0	Hold	1	–	–	﹤0.01%	4836
2016 Q2	$0	Hold	1	–	–	﹤0.01%	4806
2016 Q1	$0	Buy	+1	New	+$89	﹤0.01%	4763

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 46.14% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ladenburg Thalmann Financial Services's IMDX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Insight Molecular Diagnostics (IMDX) stake by 80% in Q4 2019, selling an estimated $3.61K and leaving 25 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5214.

Ladenburg Thalmann Financial Services first reported a position in IMDX in Q1 2016 and has held it in 12 quarters since. The position peaked at $19K in Q2 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q4 2019.

Ladenburg Thalmann Financial Services held 25 shares of Insight Molecular Diagnostics worth $1K as of Q4 2019.
Ladenburg Thalmann Financial Services sold 100 Insight Molecular Diagnostics shares in Q4 2019, an estimated $3.61K.
Insight Molecular Diagnostics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5214 holding.
Ladenburg Thalmann Financial Services first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 12 quarters since.
Ladenburg Thalmann Financial Services's Insight Molecular Diagnostics position peaked at $19K in Q2 2019.
56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.